StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the stock.
BiondVax Pharmaceuticals Trading Up 4.0 %
Shares of NASDAQ BVXV opened at $2.75 on Tuesday. BiondVax Pharmaceuticals has a 1-year low of $2.37 and a 1-year high of $22.90. The company has a market cap of $3.94 million, a PE ratio of -0.68 and a beta of 2.65. The company has a current ratio of 5.76, a quick ratio of 5.76 and a debt-to-equity ratio of 5.92. The company has a 50-day moving average of $5.62 and a two-hundred day moving average of $8.40.
Get BiondVax Pharmaceuticals alerts:BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its earnings results on Wednesday, November 30th. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.16. As a group, equities analysts expect that BiondVax Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BiondVax Pharmaceuticals
A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. grew its stake in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 163,423 shares of the company's stock after buying an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.About BiondVax Pharmaceuticals
(Get Rating)
BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza.
Further Reading
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.